Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program.
No abstract available
References:
Holstein SA, Grant SJ, Wildes TM. Chimeric antigen receptor T-Cell and bispecific antibody therapy in multiple myeloma: moving Into the future. J Clin Oncol. 2023;41(27):4416-4429.
Moreau P, Garfall AL, van de Donk N, et al. . Teclistamab in relapsed or refractory multiple Myeloma. N Engl J Med. 2022;387(6):495-505.
Garfall A, Nooka AK, van de Donk NWCJ, et al. . Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2024;42(16_Suppl):7540.
Mohan M, Monge J, Shah N, et al. . Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024;14(1):35.
Dima D, Davies JA, Ahmed N, et al. . Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience. Transplant Cell Ther. 2024;30(3):308.e1-308.e13.